<div id="content" class="col-md-12" style="">
<div data-drupal-messages-fallback="" class="hidden"/><div id="block-medsites-page-title" class="widget block">
<h1><span property="schema:name">Substance Use Disorder</span>
</h1>
</div>
<div id="block-medsites-content" class="widget block">
<article data-history-node-id="3011" role="article" about="/commodorecompendium/substance-use-disorder" typeof="schema:WebPage">
<div>
<div property="schema:text" class="field field--name-body field--type-text-with-summary field--label-hidden field__item"><div class="WordSection1">
<div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Substance Use Disorder (SUD)– Barrington Hwang, Kristopher Kast</span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">SUDs are common, complex, and chronic neuropsychiatric </span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">disorders</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> with well-described inherited risk, dysregulated neurophysiology, and multiple effective treatment modalities</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Pts w/SUD</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> face significant stigma, prior traumatic experiences in healthcare environments</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Approaching pts respectfully and fostering partnership is important to quality care </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Using</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> the term “abuse” undermines the disease model of addiction, connoting volitional “bad” behavior driving recurrent substance use</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Person</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">-centered, specific terminology: “person with opioid and alcohol use disorders”</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Avoid the qualifier “Polysubstance,” suggests the specific diagnoses are less important data</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Clarify specific diagnoses for each substance category:</span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Identify </span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">the</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> current substance exposures and distinguish use </span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">disorder</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> from unhealthy use and episodic use</span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">DSM 5 Criteria (same for most substance categories): Requires 2+ criteria met in past year; use must cause clinically significant impairment and/or distress:</span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Loss of control – larger amounts, longer time, ongoing use despite consequences, efforts/desire to reduce use</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Physiologic changes -- tolerance, withdrawal (these 2 alone do not necessarily imply a disorder if they result from prescribed therapy), craving</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Consequences – hazardous use, interpersonal problems, medical problems, failed role obligations, lost activities</span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">In the general hospital, SUD management first requires identifying and stabilizing withdrawal states to mitigate risks of severe sequelae (seizure, delirium), unintended iatrogenic harm (opioid abstinence leading to lost tolerance and post-discharge overdose), and distress-driven AMA discharge  </span></span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">General Management:</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Consider Addiction Psychiatry consultation for management of complex withdrawal states, substance use disorders and co-occurring psychiatric diagnoses, assistance with risk stratification for hospital misuse and/or hospital discharge with PICC lines for outpatient antibiotics, and differentiation of pain requiring opioid therapy and opioid use disorder</span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">At VUMC: In Epic, “Inpatient Consult to Psychiatry, Addiction Medicine” </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Team consists of addiction psychiatrists, nurse practitioners, fellows/residents, social workers, and recovery coaches</span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">If in the emergency room and not admitted, consult PAS</span></span></span></span></span></span></li>
</ul>
<p> </p>
</div>
<p> </p>
<p> </p>
<div class="WordSection2">
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Opioid</span></span></span></b><b><span style="font-size:12.0pt"><span style="background:white"><span style="line-height:107%"><span style="font-family:Palatino"><span style="color:black"> Use Disorder – Rita Hurd, David Marcovitz</span></span></span></span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Background</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Standard</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> of care is opioid stabilization with buprenorphine or methadone (in OUD) or other full agonist opioids (in chronic opioid therapy) </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Methadone</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> and buprenorphine can be ordered by any physician for inpatients </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Maintenance</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> agonist therapy should be offered to every patient, with preference for an “opt-out” approach (even for uninsured patients through state grant funding)</span></span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Presentation (Withdrawal)</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Restlessness</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">/psychomotor activation, anxiety, irritability, nausea, abdominal cramping, loose stool, diffuse musculoskeletal pain, chills, Insomnia, yawning</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Pupillary</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> dilation, piloerection, tearing, nasal congestion, diaphoresis, restless legs</span></span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Evaluation</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Clinical</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> Opioid Withdrawal Scale (COWS): quantifies severity of opioid withdrawal and allows for safer buprenorphine inductions</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Asking</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> about opioid exposure: “You’re uncomfortable. I work with a lot of people in the hospital, and some come with regular exposure to opioids from a lot of different places (their doctors, friends), should we be treating any withdrawal for you?”</span></span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Medications for Opioid Use Disorder (MOUD)</span></span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Buprenorphine</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Partial</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> agonist at the mu opioid receptor with high binding affinity </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Long</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> half-life (24-36 hours) allows for daily dosing</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">TID</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> dosing is more effective for <b>acute pain</b> (as the analgesic effect is shorter-lived)</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">OK</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> to use in renal failure/HD; may reduce dose in hepatic injury</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">All non-pregnant pts should receive buprenorphine-naloxone (e.g. Suboxone) </span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">formulations</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> to mitigate risk of diversion/injection</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Induction</span></span></b><span style="font-size:12.0pt"><span style="font-family:Palatino">:</span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Hold all opioid medication 12+ hours prior to first buprenorphine dose (typically, this opioid-free period is overnight from 9 PM to 9 AM), with a recorded COWS score &gt;8-10; </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">4 mg is given SL, monitoring for oversedation; additional 4 mg is given in 1 hour, and final 4 mg at 4 hours (total of 12 mg in first day)</span></span></span></span></span></span></span></span>
<ul>
<li style="margin-left:10px"><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Only sedation or hypopnea should prevent a full 12 mg dose</span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Typical </span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">starting</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> dose: 12-16 mg/day </span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Maintenance</span></span></b><span style="font-size:12.0pt"><span style="font-family:Palatino">: </span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">4-32 mg daily; 16mg and above to suppress opioid use</span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Requires waivered-provider</span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Acute</span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black"> Pain Management in pts using Buprenorphine:</span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">There is no contraindication to full-agonist opioid analgesia for breakthrough pain</span></span></span></span></span></span></span></span>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">If the etiology of pts pain would require opioid therapy in a non-OUD patient, do not avoid opioids; these may be used safely in the hospital </span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Peri-operative pain management: continue buprenorphine at reduced and split doses (4 mg BID or TID); will prevent withdrawal and cravings, but NOT manage new pain</span></span></span></span></span></span></span></span></li>
<li style=""><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Post-operatively: reduce opioid requirements and increase buprenorphine to home dose</span></span></span></span></span></span></span></span>
<ul>
<li style=""><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">If buprenorphine was discontinued, will require induction procedure </span></span></span></span></span></span></span></span></li>
</ul>
</li>
</ul>
</li>
</ul>
<p> </p>
</div>
<p> </p>
<div class="WordSection3">
<p><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Methadone</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Full mu opioid agonist with additional NMDA-receptor activity </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">FDA-approved for OUD when dispensed from a licensed opioid treatment program </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Better option for individuals who cannot tolerate the buprenorphine induction procedure, with significant chronic or escalating pain</span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Long t<sup>1/</sup><sub>2</sub>: 12-36 hrs; max 10 mg/d q7d, to prevent dose-stacking and delayed overdose</span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Safe in renal failure; dose reduction for hepatic injury</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Potential for QT prolongation at higher doses, warrants QTc monitoring </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Induction</span></span></span></span></b><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">:</span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">In the hospital, start at 10 mg TID, holding doses for sedation or hypopnea; lower doses if concerned for respiratory compromise or concurrent CNS depressant therapy</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Limit 40 mg in first 24 hours; then titrate 5 mg/d q3d while admitted</span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Maintenance</span></span></span></span></b><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">: </span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Must confirm dose with methadone clinic before restarting outpatient dose; until then, do not give more than initial doses (30 mg in single dose, 40 mg in first 24 hours)</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">After confirming home dose, continue as single daily dose</span></span></span></span></span></span></span></span></li>
</ul>
</li>
</ul>
<p> </p>
<p><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Naltrexone</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Mu opioid antagonist; Half-life oral ~4 hours but clinically active ~24 hrs</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">IM maintains clinically effective levels up to 30 days </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">High affinity for mu receptor --&gt; CAN precipitate withdrawal requiring 7-10 days opioid abstinence prior to initiation</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">If due for monthly injection while admitted, may substitute oral formulation until discharged to outpatient provider to receive injection</span></span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Additional Information</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Psychosocial Interventions that complement MOUD:</span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Consider referral to SUD counseling, mutual help (self-help, 12-step, AA), intensive outpatient, and short- or long-term residential treatment</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Use of other drugs NOT a contraindication to MOUD, however should encourage abstinence from other drugs during therapy (especially benzodiazepines)</span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Prescribe intranasal naloxone for overdose prevention to all OUD patients discharging from hospital, regardless of MOUD status</span></span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Alcohol Use Disorder – Barrington Hwang , Kristopher Kast</span></span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Background</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">50% of hospitalized pts drink alcohol; at-risk alcohol use is &gt;14 drinks/week or &gt;5 drinks in a sitting (for men; for women and men &gt;65, 7 per week, &gt;4 per sitting)</span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Alcohol</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> withdrawal onset occurs 6-12 hours after last drink, with 90% having non-severe course; CIWA score &lt;10 at 24-48 hours indicates low risk of worsening symptoms</span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Risk</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> of seizures greatest at 12-24 hrs, occurring in ~3% of pts; risk of delirium greatest at 48-72 hrs, occurring in ~5% </span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Risk</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> assessment</span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">RF: prior seizures/delirium, co-substance use (especially benzodiazepines), no abstinent days in past month, presenting BAL &gt;200, dysautonomia </span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">CIWA symptom-triggered protocol appropriate for pts at <b>low</b> <b>risk</b> of severe withdrawal</span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">For non-low risk pts, consider benzodiazepine/barbiturate load and standing taper; </span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Indications</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> for </span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">admission: prior severe withdrawal (withdrawal seizures or delirium), comorbidities (medical and psychiatric illness), pregnancy, significant impairment in social/occupational functioning, communication barriers, social barriers</span></span></span></span></span></span></li>
</ul>
<p> </p>
</div>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Presentation</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Acute</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> intoxication: disinhibition, slurred speech, ataxia, nystagmus</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Acute</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> Withdrawal:  nausea, vomiting, anxiety, agitation, audio-visual and tacticle </span></span><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">hallucinations</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">, headache, diaphoresis, fine motor tremor while arms and fingers outstretched, autonomic hyperactivity</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Chronic</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> heavy use: </span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Sequelae of chronic liver disease &amp; malnutrition, including thiamine deficiency</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Caine</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> criteria for Wernicke’s encephalopathy: </span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">2 or more: (1) malnutrition, (2) ataxia, (3) oculomotor abnormalities, (4) AMS</span></span></span></span></span></li>
</ul>
</li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Evaluation</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Identify</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> last use, quantity per day/week, other sedative-hypnotic use, history of withdrawal, social/occupational dysfunction, other toxic forms of alcohol compounds including methanol, ethylene glycol</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Acute</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> Alcohol</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black"> Withdrawal </span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Labs: Blood alcohol level, urine toxicology (+/- ethyl glucuronide to detect use in prior 3 days), BMP, CBC, HFTs (AST:ALT elevation 2:1), CK and </span></span><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">β</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> - hCG</span></span></span></span></span></li>
</ul>
</li>
</ul>
<ul>
<li style="margin-left:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">CIWA</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> score quantifies severity, though subject to inflation by subjective symptoms</span></span></span></span></span></li>
<li style="margin-left:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Objective Alcohol Withdrawal Scale (OAWS) is an alternative for pts at risk of over-reporting symptoms</span></span></span></span></span></li>
</ul>
<p style="margin-left:96px"> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Management</span></span></span></span></span></span></p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Acute Alcohol Withdrawal</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Most patients are appropriate for diazepam-based protocols:</span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">CIWA-based symptom-triggered for low-risk patients</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Diazepam load + standing taper for non-low risk patients</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Substitute lorazepam for pts with hepatic impairment (risk of long acting accumulation)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Benzodiazepine resistance: likely due to poor cross-tolerance, these pts  require phenobarbital load ( 8-12 mg/kg (up to 15 mg/kg) divided into 3 doses 3 hours apart)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Add folate, multivitamin, and electrolyte repletion</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">If &gt;2 Caine criteria, treat empirically for Wernicke’s encephalopathy with high-dose IV thiamine (500 mg TID IV x 3-5 days) </span></span></span></span></span></li>
</ul>
<p style="text-indent:9.0pt"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">-      Consider Addiction Psychiatry consultation for complex presentations</span></span></span></span></span></p>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Alcohol Use Disorder</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">After withdrawal stabilization, engage pt in discussion around use and educate on connection between use and presenting medical problems</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">All patients with AUD should be initiated on pharmacotherapy (MAUD) prior to discharge to mitigate risk of relapse, if consistent with patient’s goals</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Additional psychosocial treatments effective for AUD include motivational interviewing, 12-step groups (AA, SMART Recovery), cognitive behavioral therapy, sober living facilities, family therapy, contingency management, and IOP/residential facilities</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">If patient does not have abstinence goal, reduced or controlled drinking may allow for harm reduction; naltrexone and topiramate have evidence for non-abstinence outcomes</span></span></span></span></span></li>
</ul>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Pharmacologic</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> Interventions: </span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Naltrexone</span></span></b><span style="font-size:12.0pt"><span style="font-family:Palatino"> (cannot be on opioid agonist):</span></span></span></span></span>
<ul>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Need 7-10 days since last opioid before starting</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">25 mg x1 day, then titrate up to 50 mg daily; also available in q30d IM </span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Monitor liver enzymes; AST/ALT must be &lt; 3-5x ULN</span></span></span></span></span></li>
</ul>
</li>
<li style=""><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Acamprosate</span></span></b><span style="font-size:12.0pt"><span style="font-family:Palatino"> (cannot be used in severe renal impairment)</span></span></span></span></span>
<ul>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Head-to-head, inferior to naltrexone (see COMBINE trial)</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">333 mg TID, titrating to 666 mg TID dosing</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Difficult TID dosing may be helpful if framed as commitment/mindfulness practice</span></span></span></span></span></li>
</ul>
</li>
<li style=""><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Disulfiram</span></span></b></span></span></span>
<ul>
<li style="margin-left:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Infrequently used outside of extreme motivation (e.g. professional under monitoring); would not use outside specialist care</span></span></span></span></span></li>
<li style="margin-left:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Must abstain from alcohol ~2 weeks after last dose, given risk of disulfiram-ethanol reaction (DER), which can be fatal depending upon disulfiram and ethanol doses</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Topiramate</span></span></b></span></span></span>
<ul>
<li style="margin-left:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Not FDA-approved for AUD, but has significant supporting evidence</span></span></span></span></span></li>
<li style="margin-left:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Useful for individuals without abstinence goal</span></span></span></span></span></li>
<li style="margin-left:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Titrate slowly over 8 weeks to 200-300 mg/d</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Gabapentin</span></span></b><span style="font-size:12.0pt"><span style="font-family:Palatino">:</span></span></span></span></span>
<ul>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Not FDA-approved for AUD, but with some evidence</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Useful for post-acute withdrawal anxiety, insomnia, or co-occurring neuropathy</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Titrate to 900-1800 mg/d divided into TID dosing, monitoring for sedation</span></span></span></span></span></li>
<li style="margin-left: 10px;"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Risk</span></span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> of sedation/apnea if concomitant alcohol use; ensure pt educated about risk</span></span></span></span></span></li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
</div>
</article>
</div>
</div>